Inhibikase Therapeutics (IKT) EBITDA (2020 - 2024)
Historic EBITDA for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.
- Inhibikase Therapeutics' EBITDA fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$28.6 million, marking a year-over-year decrease of 4543.49%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
- Inhibikase Therapeutics' EBITDA amounted to -$12.9 million in Q4 2024, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
- In the past 5 years, Inhibikase Therapeutics' EBITDA registered a high of -$413921.0 during Q2 2020, and its lowest value of -$12.9 million during Q4 2024.
- In the last 5 years, Inhibikase Therapeutics' EBITDA had a median value of -$4.5 million in 2021 and averaged -$4.2 million.
- In the last 5 years, Inhibikase Therapeutics' EBITDA plummeted by 57364.46% in 2021 and then soared by 1505.28% in 2024.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' EBITDA stood at -$1.2 million in 2020, then crashed by 319.83% to -$5.0 million in 2021, then increased by 14.01% to -$4.3 million in 2022, then fell by 1.58% to -$4.4 million in 2023, then tumbled by 193.6% to -$12.9 million in 2024.
- Its EBITDA stands at -$12.9 million for Q4 2024, versus -$5.8 million for Q3 2024 and -$5.1 million for Q2 2024.